Table 4. Summary of retrospective... | American Society of Hematology

Table 4.

Summary of retrospective studies, comparing DOACs vs warfarin in obese patients

Study/Year	N	Inclusion criteria	Anticoagulants	Efficacy outcome: thrombotic events		Safety outcome: major bleeding events
Kido et al/2019⁴¹	128	AF, BMI > 40 kg/m² or weight > 120 kg	DOAC (D,R,A) (n = 64)	1.75%/y	RR, 0.81; 95% CI, 0.20-3.27; P = .77*	2.18%/y	RR, 0.37; 95% CI, 0.12-1.15; P = .09*
Kido et al/2019⁴¹	128	AF, BMI > 40 kg/m² or weight > 120 kg	Warfarin (n = 64)	2.07%/y	RR, 0.81; 95% CI, 0.20-3.27; P = .77*	4.97%/y	RR, 0.37; 95% CI, 0.12-1.15; P = .09*
Kushnir et al/2019⁴²	429	AF, BMI > 40 kg/m²	DOAC (R,A) (n = 277)	1.8%	P = 1.00	2.9%	OR, 0.43; 95% CI, 0.16-1.13; P = .087*
Kushnir et al/2019⁴²	429	AF, BMI > 40 kg/m²	Warfarin (n = 152)	1.3%	P = 1.00	7.9%	OR, 0.43; 95% CI, 0.16-1.13; P = .087*
Kushnir et al/2019⁴²	366	VTE, BMI > 40 kg/m²	DOAC (R,A) (n = 199)	2.0%	P = .69	1.5%	P = .60†
Kushnir et al/2019⁴²	366	VTE, BMI > 40 kg/m²	Warfarin (n = 167)	1.2%	P = .69	2.4%	P = .60†
Kalani et al/2019⁴³	180	VTE and AF, BMI ≥ 40 kg/m² and/or weight ≥ 120 kg	DOAC (D,R,A) (n = 90)	12.2%	OR, 1.11; 95% CI, 0.45-2.78; P = .82	2.2%	OR, 0.66; 95% CI, 0.11-4.04; P = .65
Kalani et al/2019⁴³	180	VTE and AF, BMI ≥ 40 kg/m² and/or weight ≥ 120 kg	Warfarin (n = 90)	11.1%	OR, 1.11; 95% CI, 0.45-2.78; P = .82	3.3%	OR, 0.66; 95% CI, 0.11-4.04; P = .65
Perales et al/2019⁴⁴	176	VTE and AF, BMI > 40 kg/m² or weight > 120 kg	DOAC (R) (n = 84)	2.4%	P = .68	8.3%‡	P = .06
Perales et al/2019⁴⁴	176	VTE and AF, BMI > 40 kg/m² or weight > 120 kg	Warfarin (n = 92)	4.3%	P = .68	2.2%‡	P = .06

Study/Year	N	Inclusion criteria	Anticoagulants	Efficacy outcome: thrombotic events		Safety outcome: major bleeding events
Kido et al/2019⁴¹	128	AF, BMI > 40 kg/m² or weight > 120 kg	DOAC (D,R,A) (n = 64)	1.75%/y	RR, 0.81; 95% CI, 0.20-3.27; P = .77*	2.18%/y	RR, 0.37; 95% CI, 0.12-1.15; P = .09*
Kido et al/2019⁴¹	128	AF, BMI > 40 kg/m² or weight > 120 kg	Warfarin (n = 64)	2.07%/y	RR, 0.81; 95% CI, 0.20-3.27; P = .77*	4.97%/y	RR, 0.37; 95% CI, 0.12-1.15; P = .09*
Kushnir et al/2019⁴²	429	AF, BMI > 40 kg/m²	DOAC (R,A) (n = 277)	1.8%	P = 1.00	2.9%	OR, 0.43; 95% CI, 0.16-1.13; P = .087*
Kushnir et al/2019⁴²	429	AF, BMI > 40 kg/m²	Warfarin (n = 152)	1.3%	P = 1.00	7.9%	OR, 0.43; 95% CI, 0.16-1.13; P = .087*
Kushnir et al/2019⁴²	366	VTE, BMI > 40 kg/m²	DOAC (R,A) (n = 199)	2.0%	P = .69	1.5%	P = .60†
Kushnir et al/2019⁴²	366	VTE, BMI > 40 kg/m²	Warfarin (n = 167)	1.2%	P = .69	2.4%	P = .60†
Kalani et al/2019⁴³	180	VTE and AF, BMI ≥ 40 kg/m² and/or weight ≥ 120 kg	DOAC (D,R,A) (n = 90)	12.2%	OR, 1.11; 95% CI, 0.45-2.78; P = .82	2.2%	OR, 0.66; 95% CI, 0.11-4.04; P = .65
Kalani et al/2019⁴³	180	VTE and AF, BMI ≥ 40 kg/m² and/or weight ≥ 120 kg	Warfarin (n = 90)	11.1%	OR, 1.11; 95% CI, 0.45-2.78; P = .82	3.3%	OR, 0.66; 95% CI, 0.11-4.04; P = .65
Perales et al/2019⁴⁴	176	VTE and AF, BMI > 40 kg/m² or weight > 120 kg	DOAC (R) (n = 84)	2.4%	P = .68	8.3%‡	P = .06
Perales et al/2019⁴⁴	176	VTE and AF, BMI > 40 kg/m² or weight > 120 kg	Warfarin (n = 92)	4.3%	P = .68	2.2%‡	P = .06

RR, rate ratio. See Tables 1 and 3 for expansion of other abbreviations.

The values are after controlling for confounders.

P value was obtained from time to major bleeding analysis.

The safety outcomes include major bleeding and clinically relevant nonmajor bleeding, 1-year follow-up in this study.